» Articles » PMID: 32123209

Patient-derived Small Intestinal Myofibroblasts Direct Perfused, Physiologically Responsive Capillary Development in a Microfluidic Gut-on-a-Chip Model

Abstract

The development and physiologic role of small intestine (SI) vasculature is poorly studied. This is partly due to a lack of targetable, organ-specific markers for in vivo studies of two critical tissue components: endothelium and stroma. This challenge is exacerbated by limitations of traditional cell culture techniques, which fail to recapitulate mechanobiologic stimuli known to affect vessel development. Here, we construct and characterize a 3D in vitro microfluidic model that supports the growth of patient-derived intestinal subepithelial myofibroblasts (ISEMFs) and endothelial cells (ECs) into perfused capillary networks. We report how ISEMF and EC-derived vasculature responds to physiologic parameters such as oxygen tension, cell density, growth factors, and pharmacotherapy with an antineoplastic agent (Erlotinib). Finally, we demonstrate effects of ISEMF and EC co-culture on patient-derived human intestinal epithelial cells (HIECs), and incorporate perfused vasculature into a gut-on-a-chip (GOC) model that includes HIECs. Overall, we demonstrate that ISEMFs possess angiogenic properties as evidenced by their ability to reliably, reproducibly, and quantifiably facilitate development of perfused vasculature in a microfluidic system. We furthermore demonstrate the feasibility of including perfused vasculature, including ISEMFs, as critical components of a novel, patient-derived, GOC system with translational relevance as a platform for precision and personalized medicine research.

Citing Articles

Bioengineering vascularization.

Landau S, Okhovatian S, Zhao Y, Liu C, Shakeri A, Wang Y Development. 2024; 151(23).

PMID: 39611864 PMC: 11698057. DOI: 10.1242/dev.204455.


Improving tumor microenvironment assessment in chip systems through next-generation technology integration.

Gaebler D, Hachey S, Hughes C Front Bioeng Biotechnol. 2024; 12:1462293.

PMID: 39386043 PMC: 11461320. DOI: 10.3389/fbioe.2024.1462293.


Prognostic value of RNA methylation-related genes in gastric adenocarcinoma based on bioinformatics.

He X, Chen X, Yang C, Wang W, Sun H, Wang J PeerJ. 2024; 12:e16951.

PMID: 38436027 PMC: 10909369. DOI: 10.7717/peerj.16951.


Deciphering the Tumor Microenvironment of Colorectal Cancer and Guiding Clinical Treatment With Patient-Derived Organoid Technology: Progress and Challenges.

Li J, Liu J, Xia W, Yang H, Sha W, Chen H Technol Cancer Res Treat. 2024; 23:15330338231221856.

PMID: 38225190 PMC: 10793199. DOI: 10.1177/15330338231221856.


Patient-Derived Microphysiological Systems for Precision Medicine.

Ko J, Song J, Choi N, Kim H Adv Healthc Mater. 2023; 13(7):e2303161.

PMID: 38010253 PMC: 11469251. DOI: 10.1002/adhm.202303161.


References
1.
Binion D, West G, Ina K, Ziats N, Emancipator S, Fiocchi C . Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology. 1997; 112(6):1895-907. DOI: 10.1053/gast.1997.v112.pm9178682. View

2.
Schirbel A, Kessler S, Rieder F, West G, Rebert N, Asosingh K . Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology. 2012; 144(3):613-623.e9. PMC: 3578104. DOI: 10.1053/j.gastro.2012.11.005. View

3.
Nandikolla A, Rajdev L . Targeting angiogenesis in gastrointestinal tumors: current challenges. Transl Gastroenterol Hepatol. 2017; 1:67. PMC: 5244743. DOI: 10.21037/tgh.2016.08.04. View

4.
Schlieve C, Mojica S, Holoyda K, Hou X, Fowler K, Grikscheit T . Vascular Endothelial Growth Factor (VEGF) Bioavailability Regulates Angiogenesis and Intestinal Stem and Progenitor Cell Proliferation during Postnatal Small Intestinal Development. PLoS One. 2016; 11(3):e0151396. PMC: 4792464. DOI: 10.1371/journal.pone.0151396. View

5.
Amin D, Hida K, Bielenberg D, Klagsbrun M . Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 2006; 66(4):2173-80. DOI: 10.1158/0008-5472.CAN-05-3387. View